Pablo Corral Shares Insights on Remnant Cholesterol and Its Role in Atherosclerotic Cardiovascular Disease
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on LinkedIn:
“A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Remnant cholesterol: the overlooked driver of residual risk in ASCVD
Despite achieving LDL-C targets with statins and novel lipid-lowering therapies, patients remain exposed to substantial residual cardiovascular risk. Emerging evidence highlights remnant cholesterol (RC)—the cholesterol content of triglyceride-rich lipoproteins—as a causal factor in atherosclerosis.
Epidemiological, genetic, and mechanistic studies consistently show that elevated RC predicts major adverse cardiovascular events, independently of LDL-C. Mendelian randomization confirms a causal role, while clinical data suggest that RC promotes endothelial dysfunction, inflammation, and thrombosis.
Although lifestyle interventions remain essential, pharmacologic strategies—including statins, fibrates, PCSK9 inhibitors, and novel gene-targeted therapies—can reduce RC levels. However, standardized measurement and clear therapeutic targets are still lacking.
RC should be recognized as a priority marker in cardiovascular prevention, guiding future strategies to reduce residual risk in high-risk populations”
Title: A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Authors: Li Wang, Qingmei Zhang, Zhiyang Wu, Xiwei Huang
Read the full article here.
Stay informed with Hemostasis Today.
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM